Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Research Domains
  1. Home
  3. Research Domains

Related Concept Videos

  • Biomedical And Clinical Sciences
  • Oncology And Carcinogenesis
  • Predictive And Prognostic Markers
  • Impaired Cd95 Expression Predisposes For Recurrence In Curatively Resected Colon Carcinoma: Clinical Evidence For Immunoselection And Cd95l Mediated Control Of Minimal Residual Disease.
  • Biomedical And Clinical Sciences
  • Oncology And Carcinogenesis
  • Predictive And Prognostic Markers
  • Impaired Cd95 Expression Predisposes For Recurrence In Curatively Resected Colon Carcinoma: Clinical Evidence For Immunoselection And Cd95l Mediated Control Of Minimal Residual Disease.

    • Related Experiment Videos

    Impaired CD95 expression predisposes for recurrence in curatively resected colon carcinoma: clinical evidence for immunoselection and CD95L mediated control of minimal residual disease.

    J Sträter1, U Hinz, C Hasel

    • 1Department of Pathology, University of Ulm, Albert-Einstein-Allee 11, 89081 Ulm, Germany. joern.straeter@medizin.uni-ulm.de

    Gut
    |April 16, 2005

    View abstract on PubMed

    Summary
    This summary is machine-generated.

    Loss of CD95 expression in colon tumors indicates a poorer prognosis. Tumor-infiltrating lymphocytes expressing CD95L may help control early-stage colon cancer, but tumor cells often lose CD95 to resist treatment.

    Related Experiment Videos

    Area of Science:

    • Oncology
    • Immunology
    • Cancer Biology

    Background:

    • Loss of CD95 expression is frequent in colon carcinoma and linked to disease progression.
    • Neo-expression of CD95 Ligand (CD95L) in tumor cells may facilitate immune evasion.

    Purpose of the Study:

    • To investigate the functional role of the CD95/CD95L system in colon carcinomas.
    • To determine the prognostic significance of CD95 and CD95L in colon cancer patients.

    Main Methods:

    • Immunohistochemistry used to assess CD95 and CD95L expression in 128 colon carcinoma samples.
    • Expression levels correlated with disease-free survival in patients with UICC stage II/III disease.

    Main Results:

    • CD95 expression was lost in the majority of tumor cells (76.6%).
    • Loss of CD95 in tumor cells correlated with adverse prognosis (p=0.046).
    • Tumor-infiltrating lymphocytes (TIL) were the primary source of CD95L; high CD95L+TIL predicted better survival in stage II disease (p=0.05).

    Conclusions:

    • Loss of CD95 on tumor cells may serve as an independent prognostic marker in colon cancer.
    • CD95L+TIL may contribute to tumor control in early stages, driving CD95 resistance.
    • CD95L expression by tumor cells is not a significant factor in colon carcinoma.